TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02468674

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Study: NCT02145780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2g of grape polyphenol extract
Description: Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
Study: NCT04211142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
Description: Laparoscopic inguinal hernia repair
Study: NCT02927873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) high dose formulation vaccine
Description: 2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study: NCT04211142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Inguinal Hernia Repair (Lichtenstein repair)
Description: Open Inguinal Hernia Repair
Study: NCT03500042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory pressure threshold device
Description: The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory pressure threshold device
Description: The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
Study: NCT03088618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal septoplasty
Description: Type of surgery
Study: NCT04082728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole
Description: Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
Study: NCT02264093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talsaclidine
Study: NCT02927873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study: NCT02264093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine
Study: NCT02927873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study: NCT03195062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Liquid test meal (fructose+glucose)
Study: NCT01766817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-986020
Study: NCT03472235

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle
Description: TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle
Description: TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session.
Study: NCT02035150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: A breakfast consisting of oatmeal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Frosted Flakes
Description: A breakfast consisting of Frosted Flakes and milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Breakfast
Description: A breakfast consisting of plain water
Study: NCT02145780

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: 2g of placebo (lactose)
Description: Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
Study: NCT02998424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Continuous infusion
Study: NCT03924453

Intervention type: DIAGNOSTIC_TEST
Intervention: Pearl Powered by Proov
Description: Participants self test in their homes and report back data via uploading onto an app and taking surveys.
Study: NCT04579276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Intrathoracic method undergone through video assisted surgery (VATS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural analgesia
Description: locoregional analgesia under ultrasound control
Study: NCT02318147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT by retention enema with fresh bacteria from healthy donor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The traditional treatment
Description: the traditional treatments according to associated guidelines
Study: NCT04064866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High yield pure PRP
Description: The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProPlaz PPC
Description: Trademarked name of an FDA-cleared product
Study: NCT03780686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine, dopamine
Description: drugs to decrease bleeding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine, dopamine
Description: drugs to decrease bleeding
Study: NCT03093818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Description: The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex).
Study: NCT03188718

Intervention type: DEVICE
Group type: OTHER
Intervention: WatchPAT Intervention
Description: Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
Study: NCT00886041

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopy
Description: subjected to laparoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ovarian stimulation
Description: ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
Study: NCT01144728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE + METFORMIN
Description: Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
Study: NCT02318147

Intervention type: DRUG
Group type: OTHER
Intervention: The traditional treatment
Description: the traditional treatments according to associated guidelines
Study: NCT01304693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg
Description: Administered as a single intravitreal injection
Study: NCT03648034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: To perform scalp nerve blocks with ropivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: To perform scalp nerve blocks with saline
Study: NCT00865514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: Subjects will have 5 mls of blood drawn for genotyping

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucine
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tyrosine
Description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
Study: NCT00542789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg once daily oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral
Study: NCT01941758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Study: NCT02622191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral domain Optical Coherence Tomography
Description: Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral domain Optical Coherence Tomography
Description: Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
Study: NCT02963792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Professionals burnout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Professionals burnout
Study: NCT00690105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus 0.1%
Description: ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone 0.005 %
Description: ointment
Study: NCT01865110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP / R-HAD
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
Study: NCT00106938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid artery stenting with filter (interventional)
Description: Carotid artery stenting with filter (interventional)
Study: NCT01865110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab SC 1400 mg every 8 weeks for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab SC 1400 mg every 8 weeks for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
Study: NCT04451161

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Beliefs and Attitudes for Successful Implementation in Schools (BASIS)
Description: BASIS blended (i.e., multifaceted and protocolized) implementation strategy, which occurs at the beginning of active implementation. BASIS is designed to facilitate observable implementation outcomes, including EBP adoption and intervention fidelity, via strategic education, motivational Interviewing, and social influence strategies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trauma-Focused Cognitive-Behavioral Therapy
Description: TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trauma-Focused Cognitive-Behavioral Therapy
Description: TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Scaffolded intervention as usual. Includes: initial assessment of trauma symptoms, psychoeducation, follow-up planning and support.
Study: NCT01941758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies